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Abstract
The processing of amyloid precursor protein (APP) to the neurotoxic pro-aggregatory Aβ peptide is controlled by the 
mechanisms that govern the trafficking and localisation of APP. We hypothesised that genes involved in endosomal protein 
sorting could play an important role in regulating APP processing and, therefore, analysed ~ 40 novel endosome-to-Golgi 
retrieval genes previously identified in a genome-wide siRNA screen. We report that phospholipase D3 (PLD3), a type II 
membrane protein, functions in endosomal protein sorting and plays an important role in regulating APP processing. PLD3 
co-localises with APP in endosomes and loss of PLD3 function results in reduced endosomal tubules, impaired trafficking 
of several membrane proteins and reduced association of sortilin-like 1 with APP.
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Abbreviations
AD  Alzheimer disease
APP  Amyloid precursor protein
CIMPR  Cation-independent mannose 6-phosphate 
receptor
GFP  Green fluorescent protein,
LOAD  Late-onset Alzheimer disease
PLD  Phospholipase D
Snx  Sorting nexin
SorL1  Sortilin-like 1
TGN  Trans-Golgi network
Vps  Vacuolar protein sorting
Introduction
The processing of amyloid precursor protein (APP) to form 
the neurotoxic pro-aggregatory Aβ peptide is believed to be 
a key initiating event in the pathogenesis of Alzheimer’s dis-
ease [1]. The trafficking and localisation of APP within the 
post-Golgi endocytic system plays an important role in regu-
lating the exposure of APP to the secretases that mediate 
its cleavage to form Aβ peptides [2, 3]. Most evidence now 
supports a model whereby the cleavage of APP to generate 
Aβ occurs in an endocytic compartment where β-secretase 
(BACE) is predominately localised [4]. Thus, mechanisms 
that direct APP away from endosomes towards either the 
Golgi complex or the cell surface are considered to be pro-
tective of APP processing to Aβ [5, 6].
The retromer complex is a key mediator of endosomal 
protein sorting and has been shown to operate in both endo-
some-to-Golgi and endosome-to-cell surface traffic, regulat-
ing the localisation of membrane proteins such as the cat-
ion-independent mannose 6-phosphate receptor (CIMPR), 
sortilin and Glut-1 [7]. The retromer complex comprises a 
stable trimeric protein complex containing Vps35, Vps26 
and Vps29 that together select membrane proteins (‘cargo’) 
for packaging into tubular carriers that form through the 
action of the other functional unit of retromer, the sorting 
nexin (Snx) dimer. For endosome-to-Golgi traffic, the Snx 
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dimer contains one copy of either Snx1 or Snx2 paired with 
either Snx5 or Snx6 [8, 9].
Another notable cargo protein for retromer is the mem-
brane protein SorL1 (also known as SorLA) that traffics 
from endosomes to the Golgi in a retromer-dependent man-
ner. SorL1 can directly associate with APP and can bind to 
the retromer cargo-selective trimer through an interaction 
with Vps26. SorL1 can thereby direct APP into the retromer-
mediated endosome-to-Golgi retrieval pathway thus pro-
tecting APP from cleavage by BACE [10–12]. Mutations in 
SorL1 can cause late-onset AD (LOAD) [13, 14] and vari-
ants of genes that regulate recruitment of the retromer com-
plex to endosomes have been shown to predispose to LOAD 
[15]. Furthermore, a point mutation in the retromer protein, 
Vps35, that results in the protein becoming unstable, may 
be causal in early-onset AD [16]. Also, it has been shown 
that expression levels of retromer proteins are reduced in 
the brains of AD patients and that loss of retromer function 
results in increased processing of APP to Aβ [17, 18].
Due to its key function in endosomal protein sorting and 
prominent role in regulating APP trafficking, there has been 
considerable interest in retromer as a potential engine of 
pathogenesis for AD [19, 20], but retromer does not operate 
in isolation in endosomal protein sorting. We have recently 
reported the results of a genome-wide siRNA screen for 
novel endosome-to-Golgi retrieval genes that may function 
alongside retromer [21]. Among the genes identified as new 
players in the endosome-to-Golgi pathway were a surprising 
number of multi-pass membrane-spanning proteins includ-
ing SFT2D2 and ZDHHC5. These two proteins are required 
for the endosome-to-Golgi retrieval of the CIMPR and both 
SFT2D2 and ZDHHC5 are localised to endosomes positive 
for retromer proteins. We hypothesised that any of the genes 
identified as novel endosome-to-Golgi retrieval genes may 
encode proteins that could function in endosomal protein 
sorting and may, therefore, regulate APP localisation and 
processing. We have undertaken an analysis of the endo-
some-to-Golgi retrieval genes and identified those genes 
that, when silenced, result in increased processing of APP 
to Aβ. We report that among the hits, the PLD3 gene exerts 
a pronounced effect on Aβ secretion. Furthermore, we show 
that PLD3 localises to retromer-positive and APP-positive 
endosomes and regulates the localisation of SorL1 and its 
association with APP.
Materials and methods
Cloning
The full-length PLD3 (WT) open reading frame (ORF) of 
490 amino acids was amplified by polymerase chain reac-
tion (PCR) using primers to introduce Bam HI and Sal I 
restriction enzyme sites to the 5′ and 3′ ends, respectively. 
All PCR products were first subcloned using the PCR blunt 
vector (Invitrogen) and sequenced. The digested ORFs were 
then subcloned into the Bgl II and Sal I sites of the pEGFP-
N3 vector (CLONTECH) for expression as a GFP-fusion 
protein in mammalian cells.
Western blotting
Cells were harvested with a sterile cell scraper and lysed in 
lysis buffer (20 mM HEPES–KOH, pH 7.2, 50 mM potas-
sium acetate, 2 mM EDTA, 200 mM sorbitol, 1% Triton 
X-100, 0.1% SDS) containing Halt™ Protease Inhibitor 
Cocktail (Thermo Scientific). Cell debris was removed by 
centrifugation at 20,000×g, 4 °C for 10 min. Supernatants 
were transferred to fresh microfuge tubes, and to an aliquot 
of the lysate appropriate volumes of 4× NuPAGE LDS sam-
ple buffer (Life Technologies) containing 50 mM DTT was 
added and heated to either 95 °C for 5 min or 70 °C for 
10 min. Samples were resolved using NuPAGE Bis–Tris 
Novex 4–12% gels (Life Technologies) and electroblotted 
to a 0.2-μm PVDF membrane using the Transblot Turbo 
Transfer System (Bio-Rad). Membranes were blocked with 
5% milk TBS–Tween 20 before incubation with primary 
antibodies overnight at 4 °C. Membranes were then probed 
with appropriate secondary antibodies conjugated with HRP 
for 1 h. Membranes were washed repeatedly in TBS–0.1% 
Tween-20 after both primary and secondary antibody incu-
bation. Blots were incubated with Pierce Super Signal or 
Millipore Immobilon enhanced chemiluminescence reagents 
for 5 min and exposed to X-ray film and developed or visu-
alised using a ChemiDoc system (Bio-Rad).
Aβ detection
For Aβ detection, appropriate volumes of 4× LDS sample 
buffer with 50 mM DTT were added to conditioned cell cul-
ture media that had been spun for 2 min at 2000 rpm and 
then heated at 95 °C for 5 min. Samples were then processed 
as described above. For detecting CTFβ and Aβ, the PVDF 
membrane was boiled post-transfer in pre-warmed PBS 
Fig. 1  PLD3 knockdown increases secreted Aβ levels. a Cell culture 
supernatants were collected from control or siRNA-treated HEK293 
cells stably expressing swAPP and analysed by Western blotting for 
Aβ. Corresponding cell lysates were also analysed by Western blot-
ting for SNX27, tubulin, PPIB and GAPDH (not shown). b Quantita-
tion of Aβ levels detected by Western blotting as in a and normalised 
to the three loading controls. Error bars indicate SD of three experi-
ments.  Statistical significance was determined by Student’s t test in 
Microsoft Excel (**P < 0.01, *P < 0.05). c Additional Western blot-
ting of APP, Aβ and CTFβ levels in lysates from control and PLD3 
knockdown cells. Tubulin and GAPDH are loading controls. The 
band intensities have been quantified and are shown in graphical form 
next to the blot
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for 5 min prior to blocking. Membranes were processed as 
described above.
Antibodies
Anti-M6PR (cation independent) antibody [2G11] (ab2733; 
Abcam).
Anti-APP (A8717; Sigma).
Anti-APP 6e10 to detect Aβ, sAPPα (SIG-39320; 
Covance).
Anti-GAPDH (Sigma).
Anti-tubulin (Sigma).
Anti-cyclophilin B (ACB0825; Atgen).
Anti-sAPPβ Swedish (6A-1; IBL).
Anti-VPS35 (SC-374372; Santa Cruz).
Anti-LAMP-1 (SC-18821; Santa Cruz).
Anti-PLD3 (HPA012800; Sigma).
Anti-transferrin receptor (13-6800; Invitrogen).
Anti-SORL1 (612633; BD Bioscience).
Anti-GFP (Seaman lab).
Anti-LBPA (MABT837; Sigma).
Anti-EEA1 (610456; BD Biosciences).
Anti-GM130 (610822; BD Biosciences).
Anti-TGN46 (Seaman lab).
Anti-MICALL1 (H00085377-B01P, Novus).
Anti-SNAP29 (gift from Andrew Peden, University of 
Sheffield, UK).
Anti-PACSIN2 (ab37615, Abcam).
Sucrose gradients
All sucrose solutions were made wt/wt (%) with ultra-pure 
sucrose in 20 mM HEPES–KOH, pH 7.2, 50 mM potas-
sium acetate, 1 mM EDTA, 1 mM DTT. The gradients were 
poured in a series of steps: 1 mL 60%, 1.0 mL 37%, 1.5 mL 
34%, 2.0 mL 32%, 2.0 mL 29%, 1.0 mL 27%, 1.5 mL 22%, 
and 0.5 mL 10%.
Cells were washed with ice-cold PBS and then resus-
pended in an ice-cold lysis buffer (20 mM HEPES–KOH, 
pH 6.8, 50 mM potassium acetate, 1 mM EDTA, 200 mM 
sorbitol, 1 mM DTT). The resulting suspension was Dounce 
homogenized in an ice-cold tissue homogenizer 15–20 times 
and then subjected to centrifugation at 500×g (5 min) to 
remove unbroken cells. Samples were loaded on top of the 
gradient which was then centrifuged in a Beckman SW41 
rotor at 30,000 × rpm for 17–18 h at 4 °C. Twelve fractions 
were collected from the top and the proteins were precipi-
tated by adding TCA to 10%. Samples were then resolved via 
SDS-PAGE and electro-transferred prior to immunoblotting.
Native IPs
Cells grown in tissue culture dishes were washed with ice-
cold PBS, then lysed using the following buffer: 20 mM 
HEPES–KOH, pH 7.2, 50 mM potassium acetate, 2 mM 
EDTA, 200 mM sorbitol, 0.1% Triton X-100 containing 
Halt™ Protease Inhibitor Cocktail. The lysates were first 
cleared by centrifugation at 10,000×g for 10 min, the result-
ing supernatant was transferred to a fresh tube to which pro-
tein A–Sepharose beads (Amersham Biosciences), pre-equil-
ibrated in lysis buffer, were added to pre-clear by incubating 
for 30 min at 4 °C on a rotating wheel. After removal of 
the beads by centrifugation at 10,000×g for 30 s, appropri-
ate antibodies were added and incubated for 2 h at 4 °C on 
a rotating wheel, and this was followed by the addition of 
protein A–Sepharose for antibody capture. After rotation 
for 1 h at 4 °C, the beads were collected by centrifugation, 
washed 4× with lysis buffer, desiccated in a SpeedVac and 
resuspended into LDS sample buffer prior to electrophoresis.
Cell culture
All cell lines were maintained in complete medium [DMEM/
high-glucose medium containing 10% foetal bovine serum 
(FBS), 2 mM l-glutamine, 100 units/mL penicillin, 100 mg/
mL streptomycin, and 250  ng/mL Amphotericin B (all 
from Life Technologies)]. HeLa and SH-SY5Y cells stably 
expressing PLD3–GFP were grown in complete medium that 
additionally contained 0.4 mg/mL geneticin (Life Technolo-
gies). To eliminate possible mycoplasma contamination cells 
were treated with Plasmocin (Invivogen, San Diego, CA, 
USA).
Transfection
Transfection of cells with constructs was carried out using 
jetPEI (Polyplus—transfection) following manufacturer’s 
instructions. Cells were harvested for further downstream 
applications 48 h post-transfection. Stable cell lines were 
established by selecting cells resistant to G418 treatment.
For siRNA transfection, cells were seeded in either 
24-well plates or 6-well plates to 30–40% confluency 24 h 
Fig. 2  PLD3–GFP co-localises with APP in the endo-lysosomal sys-
tem. HeLa cells (a) or SH-SY5Y (b) cells stably expressing PLD3–
GFP were fixed and stained for GFP and APP and imaged using full-
field (a) or confocal (b) microscopy. Colocalisation was observed 
and is highlighted in the enlarged inset areas. c HeLa cells stably 
expressing PLD3–GFP were fixed and stained for GFP and VPS35 
and imaged using full-field microscopy. Colocalisation was observed 
and is highlighted in the enlarged inset areas. d The colocalisation of 
PLD3–GFP with markers of the Golgi and post-Golgi endo/lysoso-
mal system was quantified using the M1 coefficient of colocalisation. 
e The localisation of PLD3–GFP was analysed in detail by structured 
illumination microscopy. A single 110-nm-thick section is shown. 
GFP signal is observed on the lumenal side of VPS35 endosomes, 
consistent with the predicted type II membrane topology of PLD3–
GFP. Scale bars a–c 10 μm, insets 2 μm, e 5 μm, inset 1 μm
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post-seeding. At this point, ON-TARGETplus SMARTpool 
siRNAs (final concentration of 10 nM) were delivered to 
cells using the Lipofectamine™ RNAiMAX Transfection 
Reagent (Life Technologies), following the manufacturer’s 
instructions. After transfection cells were incubated in com-
plete medium. Silencing of desired genes was carried out 
over 72 h.
Immunofluorescence
Cells grown on glass coverslips were washed with PBS 
and then fixed in 4% (w/v) paraformaldehyde for 20 min at 
37 °C. Subsequently, coverslips were rinsed 2–3 times with 
DMEM and left shaking gently for 15 min to remove all 
traces of paraformaldehyde before subsequent processing. 
Cells were permeabilised with 0.1% (v/v) Triton X-100 in 
immunofluorescence blocking buffer (IF block) (3% BSA 
in 1× PBS) for 15 min at room temperature, rinsed with 
3 × 2 ml TBS (total wash time 20 min) and incubated for 1 h 
with IF block. Coverslips were then incubated with primary 
antibodies diluted in IF block for 1–2 h at room temperature, 
rinsed with 4 × 2 ml TBS, and incubated for 30 min–2 h in 
the dark with secondary antibodies, also diluted in IF block. 
Secondary antibodies were conjugated to Alexa  Fluor® 488, 
555, 594 or 647 and obtained from Thermo Fisher. Cover-
slips were again rinsed with 4 × 2 ml TBS before mount-
ing onto slides with ProLong Gold (Life Technologies). 
Images were captured using a Zeiss Axioimager Z2 Upright 
Microscope or a Zeiss LSM880 Confocal Microscope with 
a 63 × 1.4 N.A. oil-immersion objective lens and Immersol 
518F immersion oil (all from Zeiss). Images were processed 
and analysed using the ZEISS Zen software, ImageJ and 
Volocity. For quantitation of tubulation phenotypes, 5–10 
fields containing 10–25 cells were imaged using a Zeiss 
Axioimager Z2 microscope. Cells were counted and scored 
for the presence of tubules by visual inspection.
Structured illumination microscopy (SIM)
Cells grown on 18-mm square high-performance coverslip 
(No. 1.5, Zeiss) for 24 h were washed with PBS before fixing 
in 4% formaldehyde in PBS at 37 °C for 15 min. Subse-
quent permeabilisation, blocking, staining and mounting 
steps were as for regular immunofluorescence (see above). 
SIM was performed on a Zeiss Elyra PS1 microscope at 
23 °C using a 63 × 1.4 N.A. plan-apo objective lens (Zeiss) 
and Immersol 518F (Zeiss) immersion oil. Image stacks 
were acquired using the Zeiss ZEN Black 2012 software 
for five grating phases and five grating rotations at z posi-
tions spaced 110 nm apart. Channel alignment information 
was created using a 3D array of multispectral beads imaged 
with the same instrument settings. Structured illumination 
processing and channel alignment were performed using the 
ZEN Black ELYRA edition software. The presented data are 
a region of a single slice out of a z-stack.
High‑content imaging
Cells plated in 24-well plates were fixed and stained as for 
immunofluorescence. In a final staining step cells were 
labelled with a whole cell stain (Whole Cell Stain Blue, 
Thermo Fisher). Images were acquired on a CellInsight CX7 
automated microscope and analysed using the HCS studio 
software and its spot detector bio-application. At least 400 
cells (“objects” defined by the whole cell stain) were imaged 
per well. The whole cell stain, Alexa  Fluor® 488, 555, or 647 
images were acquired sequentially using a single multi-pass 
filter set. A 20× objective lens was used.
FACS
Cells were resuspended in complete medium containing 20% 
FCS (enhanced medium), and GFP-expressing cells were 
sorted using the BD Influx cell sorter. Cells were allowed 
to recover in enhanced medium for 24 h and then used for 
further applications.
Results
To identify genes that have a role in APP processing, we 
selected  ~  40 high-confidence validated hits from the 
genome-wide siRNA screen [21] and tested each for a 
role in regulating APP processing to Aβ by silencing the 
expression of the gene-of-interest by siRNA. As positive 
controls we also silenced expression of Vps35 and Snx27 
individually as both have been shown to cause increased 
Aβ production when silenced [18, 22]. The level of the Aβ 
peptide secreted into the media was assessed by Western 
blotting. Cell lysates were also generated and intracellular 
proteins (e.g. Snx27) were detected by Western blotting. In 
Fig. 1a, data from the Aβ secretion assay are shown for 14 
of the endosome-to-Golgi retrieval screen hits. Levels of 
Fig. 3  Silencing of PLD3 perturbs endosomal protein sorting. a Con-
trol SH-SY5Y cells and cells treated with PLD3 siRNA were lysed 
and analysed by Western blotting. Levels of SorL1 appear reduced 
whilst other proteins such as the transferrin receptor (TFRC) are mod-
estly increased. b Western blot data from three independent experi-
ments are shown graphically. c, d Control and PLD3-silenced HeLa 
cells were fixed and stained for various endosomal proteins, lysoso-
mal markers and transmembrane proteins. Scale bars = 20 μm. Quan-
titation of the changes in immunofluorescent localization of LAMP1 
(e), CIMPR (f) and APP (g) upon PLD3 knockdown using automated 
microscopy. Statistical significance was determined by Student’s t test 
in Microsoft Excel (**P < 0.01, *P < 0.05)
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Aβ vary across the different knockdowns with the PLD3 
and MPP2 knockdowns generating phenotypes similar to the 
Snx27-positive control whilst the SH3PXD2 and KCNK3 
knockdowns appear to reduce secreted Aβ. In Fig. 1b, levels 
of secreted Aβ from ~ 40 of the high-confidence hits are 
shown graphically from triplicate experiments after nor-
malisation to loading controls. The PLD3 knockdown gives 
the most pronounced increase in Aβ levels and was selected 
for further study. Increased processing of APP to Aβ would 
be expected to result in increased levels of sAPPβ and the 
C-terminal fragment resulting from beta cleavage (Ctf-β) 
and this is what we observe in a PLD3 knockdown (Fig. 1c). 
To confirm that the increased Aβ detected after PLD3 knock-
down is not the result of off-target effects we analysed each 
of the four siRNA comprising the PLD3-targetting Smart-
Pool siRNA. Two of the four siRNA (sequences 10 and 11) 
generated increased Aβ similar to the SmartPool siRNA (see 
Supplemental Figure S1).
If PLD3 is influencing the processing of APP it would be 
predicted to localise to compartments that APP may traffic 
through, e.g. endosomes or the Golgi complex. To investi-
gate the localisation of PLD3, a GFP tag was added to the 
C terminus of PLD3 and HeLa cells were transfected with 
the PLD3–GFP construct. PLD3 is a type II membrane pro-
tein and, therefore, the GFP moiety will be on the lumenal 
side of the membrane. The PLD3–GFP construct was found 
to colocalise with a similar construct tagged with mcherry 
that has been reported previously by Sleat et al. [23]. The 
PLD3–GFP construct also fractionated similar to endog-
enous PLD3 when analysed by sucrose density gradient 
fractionation indicating that it traffics in a manner similar to 
the native PLD3 protein (see Supplemental Figure S2). In 
Fig. 2a, HeLa cells stably expressing PLD3–GFP were fixed 
and labelled with antibodies against APP. We observed that a 
proportion of the PLD3–GFP colocalised with APP. A simi-
lar degree of colocalisation was observed for PLD3–GFP 
and APP in neuroblastoma SH-SY5Y cells (Fig. 2b) and 
PLD3–GFP was detected in endosomes positive for the ret-
romer protein VPS35 (Fig. 2c). Quantitation of the colo-
calisation of the PLD3–GFP protein with endo/lysosomal- 
and Golgi-localised proteins including Lamp1, TGN46 and 
APP confirmed that PLD3–GFP was present in Golgi and 
post-Golgi membranes in both HeLa and SH-SY5Y cells 
(Fig. 2d) An examination of the PLD3–GFP localisation was 
conducted using super-resolution microscopy and is shown 
in Fig. 2e. Here the GFP fluorescence is detected inside the 
lumen of Vps35-positive endosomal membranes. Lamp1-
positive structures are present nearby. We confirmed that 
PLD3 is a type II membrane protein by generating a con-
struct where the GFP moiety is present at the N terminus 
and, therefore, should be orientated towards the cytoplasm 
and inaccessible to anti-GFP antibodies applied to the out-
side of unpermeabilised cells (see Supplemental Figure S3).
The colocalisation we observed between the PLD3–GFP 
and endosomal markers such as VPS35 indicated that PLD3 
may play a role in regulating endosomal protein sorting—
consistent with its identification as a novel endosome-to-
Golgi retrieval gene through the genome-wide siRNA screen 
[21]. We, therefore, investigated the levels and localisation of 
several membrane proteins that transit through endosomes. 
In Fig. 3a, a Western blot of membrane proteins from the 
neuroblastoma cell line SH-SY5Y is shown. We observed 
that levels of SorL1 were reduced whilst other membrane 
proteins, e.g. the transferrin receptor (TFRC) and Lamp1 
appeared increased. In Fig. 3b, Western blot data from 
three independent experiments have been quantified. Loss 
of PLD3 function by siRNA knockdown in the SH-SY5Y 
cells appeared to increase levels of the lysosomal marker 
protein, Lamp1 and this was confirmed in HeLa cells treated 
with siRNA targeting PLD3 expression. In Fig. 3c, control 
and PLD3 knockdown cells have been labelled with antibod-
ies against Lamp1 and VPS35 or antibodies against APP and 
CIMPR (Fig. 3d). Using an automated microscope we quan-
tified the fluorescence intensity after PLD3 knockdown or 
for comparison knockdown of the retromer protein, VPS35. 
We observed a gain in the Lamp1 fluorescence intensity 
(see Fig. 3e). A similar effect was observed for the CIMPR 
and APP proteins (see Fig. 3f, g). Thus, changes in mem-
brane protein levels measured using western blot analyses 
of lysates from SH-SY5Y cells were recapitulated in HeLa 
cells using automated microscopy.
In previous studies we have observed that conditions that 
perturbed endosomal protein sorting often lead to changes 
in the numbers of Snx1-positive tubules. For example, 
knockdown of the WASH complex results in increased 
Snx1 tubules but loss of EHD1 expression has the opposite 
effect. [24, 25]. Whilst we were examining PLD3 knock-
down cells for changes in membrane protein localisation, 
we noticed that there appeared to be fewer tubular structures 
Fig. 4  Loss of PLD3 impairs endosomal tubule formation or stabil-
ity. a HeLa cells were treated with siRNA to abolish PLD3 expres-
sion and then fixed and labelled with anti-Snx1. Arrow heads indi-
cate tubules that were rarely observed in PLD3 knockdown cells. 
Scale bar = 50 μm. b As in a, but cells were labelled with antibodies 
against the MICALL1 protein. Scale bar = 50 μm. c Snx1-decorated 
endosomal tubules were imaged in control HeLa cells, PLD3 siRNA-
treated HeLa cells and HeLa cells stably expressing PLD3–GFP. 
Tubules were quantified. The results of two independent experiments 
are shown (average ± SD) with more than 50 cells counted in each 
condition in each experiment. Statistical significance was determined 
by Student’s t test in Microsoft Excel (*P  <  0.05). d MICALL1 
tubules were counted in three independent experiments, scoring more 
than 75 cells each time for each condition. Tubules that were PAC-
SIN2- or SNAP29 positive were also counted in more than 100 cells 
and the data presented graphically. e Cell lysates were analysed by 
Western blotting. Loss of PLD3 expression does not affect SNX1 lev-
els but does result in reduced levels of MICALL1 and the associated 
proteins (i.e. EHD1, PACSIN2 and SNAP29)
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positive for Snx1. In Fig. 4a, control and PLD3 knockdown 
of HeLa cells have been labelled with antibodies against 
Snx1. Tubules are evident in the control cells but generally 
absent in the PLD3 knockdown cells. We observed a similar 
loss of tubules positive for MICALL1, a protein that func-
tions with EHD1, Pacsin2 and Snap29 in mediating traffic 
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from recycling endosomes to the cell surface [26, 27] (see 
Fig. 4b and Supplemental Figure S4 for images of Pac-
sin2- and Snap29-positive tubules). When tubule numbers 
were determined, the knockdown of PLD3 caused a ~ 40% 
reduction in Snx1 tubules whereas Snx1-tubules increased 
in cells stably expressing the PLD3–GFP construct. The 
loss of MICALL1 tubules after PLD3 knockdown was more 
pronounced (Fig. 4d) but it should be noted that Western 
blotting of cell lysates revealed a marked loss of MICALL1 
protein and a reduction in the levels of proteins associated 
with MICALL1 including EHD1, Pacsin2 and Snap29 (see 
Fig. 4e). We confirmed that the loss of MICALL1 tubules 
after knockdown of PLD3 was not an off-target effect by 
analysing MICALL1 tubules in cells where single siRNA 
oligos were used to silence PLD3 expression (see Supple-
mental Figure S5).
The reduction in Snx1-positive tubules observed after loss 
of PLD3 expression, and the reduction in other endosomal 
trafficking machinery such as MICALL1 would be expected 
to affect many proteins that traffic through endosomes. 
Given that PLD3 knockdown elicited a marked increase in 
processing of APP to Aβ, we hypothesised that key proteins 
that govern APP localisation and/or processing would be 
similarly affected. The SorL1 protein associates with APP to 
regulate its localisation and processing [11–13]. We, there-
fore, investigated whether SorL1 could associate with APP 
after PLD3 knockdown. In Fig. 5a, cell lysates were treated 
with anti-APP antisera to recover APP and associated pro-
teins. We observed a pronounced reduction in the amount 
of SorL1 associated with APP in PLD3 knockdown lysates. 
We next investigated the localisation of SorL1 but due to 
limitations of the anti-SorL1 antisera we could not deter-
mine SorL1 localisation by fluorescence microscopy. There-
fore, we examined the subcellular distribution of SorL1 by 
sucrose density gradient fractionation in control and PLD3 
knockdown lysates. In Fig. 5b, after knockdown of PLD3, 
the SorL1 protein is shifted on sucrose density gradients 
being predominately present in lighter fractions (e.g. frac-
tions 6 and 7) whereas SorL1 is generally detected in denser 
fractions in lysates from control cells. The distribution of the 
CIMPR is also altered but the transferrin receptor (TFRC) is 
not observably different.
Discussion
Here we report that PLD3, a type II transmembrane protein, 
is an important regulator of endosomal protein sorting and 
loss of PLD3 function results in increased processing of 
amyloid precursor protein (APP) to Aβ—possibly as a con-
sequence of the mistrafficking of SorL1. PLD3 is a member 
of the phospholipase D family and, therefore, predicted to 
function in the conversion of phosphatidyl choline (PC) to 
phosphatidic acid (PA) [28] but has yet to be formally shown 
to possess this activity.
Our studies of endosome-to-Golgi retrieval revealed 
PLD3 to be required for the efficient retrieval of a CD8-
CIMPR reporter protein—PLD3 is one of ~ 40 high-con-
fidence hits from a genome-wide siRNA screen for novel 
endosome-to-Golgi retrieval genes [21]. As endosomal pro-
tein sorting has been intimately linked with regulating APP 
localisation and processing, we hypothesised that any of the 
novel endosome-to-Golgi retrieval genes could be important 
regulators of APP processing. We, therefore, tested the ~ 40 
high-confidence hits for a role in controlling APP process-
ing and found that loss of PLD3 markedly increased APP 
processing to Aβ, even more than the knockdown of VPS35 
or SNX27, both of which have been shown to regulate APP 
processing [18, 22]. Interestingly, mutations in PLD3 have 
been linked to Alzheimer’s disease [29, 30] although this 
has become somewhat controversial with subsequent stud-
ies refuting the initial report [31–34]. The genome-wide 
screen we undertook for novel endosome-to-Golgi retrieval 
genes was an unbiased gene-by-gene search for new players 
in endosomal protein sorting and revealed a role for PLD3 
[21]. The examination of the ~ 40 high-confidence hits for 
a role in regulating APP processing that we report here is a 
similar unbiased approach.
The localisation of PLD3 was determined to be endoso-
mal and, at least partially, lysosomal. The localisation of 
PLD3 to lysosomes is consistent with other reports describ-
ing the localisation of PLD3 [23]. We, however, observed 
a significant pool of the PLD3 protein in structures that 
were positive for retromer proteins (i.e. Vps35), and sig-
nificantly, also positive for APP. Thus, it seems likely that 
PLD3 traffics through the post-Golgi endocytic system and 
may, therefore, have wide-ranging and pleiotropic effects on 
endosomal protein sorting. Indeed loss of PLD3 function did 
result in changes in levels of several membrane proteins that 
traffic through endosomes including the transferrin receptor, 
the CIMPR and Lamp1. The levels of other proteins that 
operate in endosomal protein sorting also appeared changed 
such as MICALL1. It has been reported that the coiled-coil 
domain of MICALL1 binds to phosphatidic acid (PA) [27] 
and in doing so provides a key interaction between recycling 
Fig. 5  Silencing of PLD3 perturbs SorL1 association with APP and 
alters SorL1 subcellular distribution. a Control or PLD3 siRNA-
treated SH-SY5Y cells were lysed and treated with monoclonal anti-
APP antibody to immunoprecipitate (IP) APP. Lysates (right panel) 
and co-immunoprecipitated proteins (left panel) were analysed by 
Western blotting, the SorL1 protein is indicated by an arrow. The 
band intensities have been quantified and are shown in graphical form 
next to the blot. b Control and PLD3-silenced SH-SY5Y cells were 
lysed and subjected to centrifugation on a 10–60% sucrose gradient. 
Fractions (1–12) were collected and analysed by Western blotting. 
The fractionation profile of SorL1 is markedly altered upon PLD3 
knockdown
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endosomes and the MICALL1 complex that includes EHD1 
and Pacsin2 (also known as Syndapin2).
Thus, the loss of PLD3 may be affecting proteins such 
as MICALL1 through production of PA. It should be noted, 
however, that the predicted catalytic domain of PLD3 is on 
the lumenal side of the protein and thus if PLD3 is responsi-
ble for PA production on the cytoplasmic face of endosomes, 
a lipid flippase may be required to translocate the PA from 
the lumenal side to the cytoplasmic side. There have been 
reports recently from studies in yeast that the Neo1 lipid 
flippase localises to endosomes and is trafficked by Snx3, 
a retromer-associated protein [35]. Thus, it is plausible that 
PLD3 exerts it effects on endosomal protein sorting through 
its function as a phospholipase D enzyme. It does not, how-
ever, appear to be essential for the production of lysobispho-
sphatidic acid (LBPA). The LBPA lipid has been reported to 
be a marker of late endosomes and lysosomes and has been 
linked with multivesicular body formation [36] but we did 
not detect any significant changes in LBPA levels in cells 
treated with siRNA to knockdown PLD3 (see Supplemental 
Figure S6).
Loss of PLD3 function did induce a reduction in Snx1-
positive tubules, altered SorL1 and CIMPR distribution on 
sucrose density gradients and, most tellingly, resulted in a 
profound reduction in the amount of SorL1 associated with 
APP. These observations can explain why loss of PLD3 
results in increased processing of APP to Aβ. The reduced 
Snx1 tubules would be predicted to impair the endosome-to-
Golgi trafficking of both SorL1 and CIMPR resulting in their 
mislocalisation. Thus, APP trafficking would be impacted 
and increased processing to Aβ the end result. Other effects 
of the loss of PLD3 (e.g. reduced MICALL1) could com-
pound the endosomal protein sorting defect and also lead to 
altered APP processing. It should, however, be noted that 
genetic knockout of PLD3 in mice did not result in altered 
APP processing or increased Aβ levels [34]. Why the knock-
out of PLD3 behaves differently from the knockdown is not 
clear but it is possible that some form of adaptation to the 
loss of PLD3 has occurred in the knockout mice, possibly 
through upregulation of phospholipase D family members, 
PLD1 or PLD2—adaptation that may not occur in the time 
frame of an RNAi-mediated knockdown.
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